Anzeige
Mehr »
Freitag, 06.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3EWMJ | ISIN: US8989201038 | Ticker-Symbol: PL3
Tradegate
05.06.25 | 12:36
2,440 Euro
-3,94 % -0,100
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
TUHURA BIOSCIENCES INC Chart 1 Jahr
5-Tage-Chart
TUHURA BIOSCIENCES INC 5-Tage-Chart
RealtimeGeldBriefZeit
2,4602,52017:08
2,4602,52017:05

Aktuelle News zur TUHURA BIOSCIENCES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiTuHURA Biosciences sammelt 15,5 Millionen US-Dollar für Krebsstudien1
DiTuHURA Biosciences raises $15.5 million for cancer trials1
15.05.TuHURA Biosciences, Inc./NV - 10-Q, Quarterly Report1
15.05.TuHURA Biosciences, Inc./NV - 8-K, Current Report2
15.05.TuHURA Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides a Corporate Update232Anticipates initiating the Company's Phase 3 accelerated approval trial of IFx-Hu2.0 as adjunctive therapy with Keytruda® (pembrolizumab) as a first-line therapy...
► Artikel lesen
TUHURA BIOSCIENCES Aktie jetzt für 0€ handeln
07.05.TuHURA Biosciences, Inc./NV - 8-K, Current Report-
06.05.TuHURA Biosciences, Inc./NV - S-4/A, Registration of securities, business combinations3
05.05.TuHURA Biosciences startet Studie für Therapie bei metastasiertem Krebs2
05.05.TuHURA Biosciences begins trial for metastatic cancer therapy1
05.05.TuHURA Biosciences, Inc. Initiates Phase 1b/2a Study of IFx-Hu2.0 as an Adjunctive Therapy to Keytruda (pembrolizumab) in First Line Treatment for Metastatic Merkel Cell Carcinoma of Unknown Primary Origin (MCCUP)67Phase 1b /2a trial designed to evaluate the safety and feasibility of IFx-Hu2.0 in combination with Keytruda® when administered via Interventional Radiology (IR)...
► Artikel lesen
28.04.TuHURA Biosciences, Inc.: TuHURA Biosciences and Kineta Present Updated Results from Kineta's Phase I-II Study of KVA12123 and TuHURA's Mechanism of IFx-Hu2.0 Responses After Anti-PD-1 Therapy Failure in Advanced Melanoma ...91Kineta presents updated clinical data from VISTA-101 trial of KVA12123, demonstrating>90% VISTA receptor occupancy at 1,000mg dose level throughout the trial's every...
► Artikel lesen
15.04.XFRA NEW INSTRUMENTS AVAILABLE ON 15.04.2025221The following instruments on XETRA do have their first trading 15.04.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 15.04.2025 Aktien 1 US13970R1095 Capita PLC ADR 2 CA46123W2031...
► Artikel lesen
07.04.TuHURA Biosciences stellt neuen Leiter für Arzneimittelentwicklung ein2
01.04.TuHURA Biosciences, Inc./NV - 8-K, Current Report1
01.04.TuHURA Biosciences, Inc. Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update111Phase 3 IFx-2.0 accelerated approval trial as adjunctive therapy with Keytruda® (pembrolizumab) in 1st line therapy for advanced Merkel cell carcinoma (MCC) planning...
► Artikel lesen
31.03.TuHURA Biosciences, Inc./NV - 10-K, Annual Report1
18.03.TuHURA Biosciences, Inc./NV - 8-K, Current Report1
11.03.TuHURA Biosciences, Inc.: TuHURA Biosciences, Inc Appoints Craig L. Tendler M.D., Former Vice President, Oncology Clinical Development, Diagnostics, and Global Medical Affairs, Johnson & Johnson Innovative Medicine Research & Development, to its Board464Dr. Tendler oversaw 30 Major Drug Approvals, including worldwide approvals for J&J's transformational treatments in hematologic malignancies, prostate, lung and bladder cancersDr. Tendler also oversaw...
► Artikel lesen
10.03.TuHURA Biosciences, Inc. to Present at the 37th Annual ROTH Conference213Live webcast fireside chat on Tuesday, March 18th at 8:30 AM PT TAMPA, FL / ACCESS Newswire / March 10, 2025 / TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA"), a Phase 3 registration-stage immuno-oncology...
► Artikel lesen
19.02.TuHURA Biosciences, Inc. Participates in the Virtual Investor "Top 5 for '25" On-Demand Conference221On-demand video webcast now available here TAMPA, FL / ACCESS Newswire / February 19, 2025 / TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA"), a Phase 3 registration-stage immune-oncology company developing...
► Artikel lesen
Weiter >>
42 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1